Analysts have clear opinions on EGRX.

There are 2 analysts on the Wall offering 12 month price targets for Eagle Pharmaceuticals in the last 3 months. The average price target is $60.00 with a high forecast of $62.00 and a low forecast of $58.00. The average price target represents a 2.99% increase from the last price of $58.26.
Eagle Pharmaceuticals, Inc. (EGRX) is followed by 2 analysts on the street.

Brandon Folkes from Cantor Fitzgerald rates it a Hold with a target of $58.00.

Similarly, 2 months ago Randall Stanicky of RBC Capital Reiterated a Buy with a target of $62.00.

The consensus on the street is Moderate Buy.

What does Eagle Pharmaceuticals, Inc.(EGRX) do ?
Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Eagle Pharmaceuticals, Inc. (EGRX) Insider Trades

Multiple company employees have indulged in significant insider trading. Eagle Pharmaceuticals, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

Dir, Hudson Executive Capital LP : S – Sale(-$1,074,715) of EGRX in the trading session of 2019-10-24.

Dir Hudson Executive Capital LP : S – Sale(-$664,924) of EGRX in the trading session of 2019-10-21.

Dir Hudson Executive Capital LP : S – Sale(-$972,745) of Eagle Pharmaceuticals, Inc. in the trading session of 2019-10-16.

Looking for stocks just like EGRX?

Based on Wall Street analyst research, several stocks are similar to EGRX
They are:
– NVS [Info can be found here: ]
– TEVA [Info can be found here: ]
– SPPI [Info can be found here: ]